Vadadustat Patent Expiration
Vadadustat was first introduced by Akebia Therapeutics Inc
Vadadustat Patents
Given below is the list of patents protecting Vadadustat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vafseo | US11324734 | Compositions and methods for treating anemia | Mar 31, 2036 | Akebia |
| Vafseo | US11844756 | Compositions and methods for treating anemia | Mar 31, 2036 | Akebia |
| Vafseo | US10149842 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US11065237 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US9701636 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US9987262 | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | Nov 14, 2034 | Akebia |
| Vafseo | US11857543 | Compositions and methods for treating anemia | Jun 09, 2034 | Akebia |
| Vafseo | US12569474 | Compositions And Methods For Treating Anemia | Jun 04, 2034 | Akebia |
| Vafseo | US8323671 | Prolyl hydroxylase inhibitors and methods of use | Apr 03, 2028 | Akebia |
| Vafseo | US7811595 | Prolyl hydroxylase inhibitors and methods of use | Mar 13, 2028 | Akebia |
| Vafseo | US8343952 | Prolyl hydroxylase inhibitors and methods of use | Aug 14, 2027 | Akebia |
| Vafseo | US8598210 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
| Vafseo | US8940773 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
| Vafseo | USRE47437 | Prolyl hydroxylase inhibitors and methods of use | Jun 26, 2027 | Akebia |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vadadustat's patents.
Latest Legal Activities on Vadadustat's Patents
Given below is the list recent legal activities going on the following patents of Vadadustat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Nov, 2025 | US9987262(Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Oct, 2025 | US11324734 |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8940773 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8343952(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8598210(Litigated) |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8323671(Litigated) |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US8343952(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8323671(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US7811595(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US8940773 |
Vadadustat's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vadadustat:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis | Akebia Therapeutics | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury | Paul Potnuru | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2, PHASE3 |
| Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | Geoff Block | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE3 |
| Vafseo Outcomes In-Center Experience | USRC Kidney Research | NA |
ACTIVE NOT RECRUITING
(Mar 1, 2026)
| PHASE3 |